Cardiovascular Diseases Clinical Trial
To develop a comprehensive protocol for assessing cardiovascular reactivity to stressors, for use in epidemiological and clinical investigations of cardiovascular diseases in healthy populations.
BACKGROUND:
Cardiovascular reactivity (CVR) is the change in a cardiovascular parameter in response to a
discrete environmental stimulus. A leading theory linking behavior to cardiovascular
diseases such as atherosclerosis and hypertension proposed that an exaggerated physiological
response to a psychological challenge increased the risk for development of disease. Such a
link had not been established conclusively in 1988. To a considerable extent, this might
have been due to the fact that numerous approaches were devised to elicit and measure CVR.
Furthermore, no single test or combination of tests was available which would be suitable
for administering to large numbers of individuals who differed in age, gender, cultural or
ethnic background, and socioeconomic status, as would be required for definitive prospective
studies of reactivity and cardiovascular disease.
A conference sponsored by the NHLBI and the University of Pittsburgh in 1984 comprehensively
reviewed the concept of reactivity, its measurement, and its hypothesized relationship to a
disease process. The value of CVR is that it provides an estimation of the changes in
cardiovascular function in response to the challenges of daily life, and thus may serve as a
better marker or predictor of cardiovascular disease risk than the usual 'casual'
measurements. Essential hypertension appears to be a multi-factorially determined disorder,
whose etiology encompasses different elements for different individuals. Physiological
changes induced by excessive cardiovascular reactivity are among the mechanisms suggested to
account for the transition from borderline to established hypertension. In this model,
episodic cardiovascular activation elicited by behavioral challenges leads to autoregulatory
adjustments culminating in elevated blood pressure. An alternative interpretation is that
both elevated CVR and elevated blood pressure are reflections of underlying nervous system
pathology. Prospective studies, using appropriate behavioral designs and a standardized
protocol to assess cardiovascular reactivity could distinguish between these alternatives.
The possible role of cardiovascular reactivity in coronary heart disease was supported by
evidence from both basic and clinical studies. The hemodynamic forces resulting from
turbulence and shear stress at curves and bifurcations of the coronary arteries had been
cited as responsible for the greater degree of atherosclerosis in high heart rate, as
opposed to low heart rate animals. Monkeys with large elevations of heart rate in response
to psychological arousal developed significantly more atherosclerosis. Although the above
findings had not been confirmed in humans as of 1988, a substantial majority of studies
reported greater reactivity of Type A subjects during stress.
Although the evidence was suggestive and the mechanism plausible, stress-induced
cardiovascular reactivity had not been investigated as a risk factor for cardiovascular
disease. In addition to basic research to determine the parameters and physiological
determinants of reactivity, clinical and epidemiological studies were needed to establish
whether this association was reliable. Especially needed were prospective, longitudinal
studies of the association between reactivity and disease.
The Clinical Applications and Prevention Advisory Committee of the National Heart, Lung, and
Blood Institute recommended the development of this study in February 1987. The National
Heart, Lung, and Blood Advisory Council approved the concept in May 1987. A Request for
Applications was released in August 1987 and awards made in July 1988.
DESIGN NARRATIVE:
Investigators at the University of Miami evaluated cardiovascular and hormonal functions at
rest and after standardized manipulations designed to evoke autonomic nervous system
arousal. Two hundred and fifty-six subjects were enrolled into a 2 (male, female) x 2
(Black, white) x 2 (25-44 years, 55-64 years) x 2 (Miami, Durham) design. Subjects were
compared across a broad range of socioeconomic status. Each subject was scheduled for three
laboratory sessions. Sessions 1 and 2 were two weeks apart. Session 3 was six months later.
During the sessions, individuals were subjected to a forehead cold pressor stimulus, a video
game, and an evaluative speech stressor. Noninvasive cardiovascular measures assessed
included heart rate, cardiac output, peripheral resistance, Heather Index, pre-ejection
period, left ventricular ejection period, and diastolic, systolic, and mean arterial blood
pressure. On the same day as the laboratory session, subjects wore an ambulatory impedance
and electrocardiogram monitor at work and at home. The following day subjects wore an
ambulatory blood pressure monitor at work and at home. Data were analyzed in terms of
stability of baseline values, differences in laboratory reactivity between groups,
differences in reactivity between tasks, reliability of responses to tasks across sessions,
differences in reactivity as an individual difference variable, and generalizability of
reactivity in the laboratory to cardiovascular function observed in more naturalistic
settings. Improved procedures were developed for monitoring impedance cardiographic and
electrocardiographic activity.
Investigators at the University of Pittsburgh developed a battery of tests to elicit
differential vascular, cardiac inotropic and chronotropic responses. Each task was based on
a computer-driven video game which permitted a standardized task presentation and multiple
response measurement. During the initial prototyping year, items were selected to maximize
reliability, validity, and applicability to diverse demographic groups. Circadian ambulatory
studies in this year established optimal baselines for reactivity assessment.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|